Brokers Offer Predictions for Zoetis’ Q3 Earnings (NYSE:ZTS)

Zoetis Inc. (NYSE:ZTS) – Research analysts at Leerink Partnrs raised their Q3 2025 earnings estimates for Zoetis in a research note issued to investors on Tuesday, May 6th. Leerink Partnrs analyst D. Clark now forecasts that the company will post earnings per share of $1.68 for the quarter, up from their prior forecast of $1.64. The consensus estimate for Zoetis’ current full-year earnings is $6.07 per share. Leerink Partnrs also issued estimates for Zoetis’ Q4 2025 earnings at $1.46 EPS, FY2025 earnings at $6.22 EPS, FY2026 earnings at $6.88 EPS, FY2027 earnings at $7.48 EPS and FY2028 earnings at $8.07 EPS.

ZTS has been the topic of several other reports. StockNews.com upgraded Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, March 7th. Morgan Stanley decreased their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Stifel Nicolaus lowered their target price on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating on the stock in a research note on Monday, April 14th. UBS Group reduced their price target on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating for the company in a research report on Wednesday. Finally, Barclays increased their price objective on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $212.13.

Zoetis Stock Performance

NYSE:ZTS opened at $159.96 on Friday. The business’s fifty day moving average is $157.27 and its 200 day moving average is $166.22. The firm has a market cap of $71.37 billion, a price-to-earnings ratio of 29.24, a PEG ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis has a 52-week low of $139.70 and a 52-week high of $200.33.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The business had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Zoetis’s revenue was up 1.4% compared to the same quarter last year. During the same period in the previous year, the business earned $1.38 EPS.

Insider Transactions at Zoetis

In related news, Director Willie M. Reed sold 1,210 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now owns 11,245 shares in the company, valued at $1,868,244.30. The trade was a 9.71 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the transaction, the executive vice president now owns 15,781 shares in the company, valued at $2,682,770. The trade was a 2.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,862 shares of company stock valued at $312,254. Insiders own 0.18% of the company’s stock.

Institutional Trading of Zoetis

Several institutional investors have recently added to or reduced their stakes in the business. Atlantic Edge Private Wealth Management LLC boosted its holdings in Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after acquiring an additional 140 shares during the period. Rakuten Securities Inc. lifted its position in Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 166 shares during the last quarter. Navigoe LLC bought a new stake in Zoetis in the fourth quarter valued at approximately $30,000. Cornerstone Planning Group LLC boosted its stake in shares of Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after purchasing an additional 88 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. grew its holdings in shares of Zoetis by 87.6% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company’s stock worth $42,000 after purchasing an additional 120 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.